The gallium-68 market is gaining significant traction globally due to its increasing use in advanced diagnostic imaging, particularly in oncology. Gallium-68, a positron-emitting radioisotope, plays a crucial role in positron emission tomography (PET) scans, enabling accurate detection of tumors and chronic diseases. The growing prevalence of cancer and neurological disorders, coupled with advancements in nuclear medicine, is creating a strong demand base for gallium-68-based radiopharmaceuticals. As healthcare systems worldwide continue to adopt precision diagnostics, the market is witnessing stable and sustained expansion.
The Gallium-68 Market Analysis highlights a consistent growth trajectory supported by technological innovations and rising clinical adoption. The gallium-68 market forecast can help stakeholders in this marketplace outline their growth strategies. The gallium-68 market is projected to grow from US$ 782.36 million in 2022 to US$ 1,070.34 million by 2030; it is estimated to record a CAGR of 4.0% during 2022–2030. This growth reflects the increasing reliance on nuclear imaging techniques for early disease diagnosis and treatment planning.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00029992
Market Overview
Gallium-68 is widely used in radiolabeling compounds for PET imaging, especially for detecting prostate cancer and neuroendocrine tumors. Its short half-life of approximately 68 minutes makes it ideal for diagnostic procedures, ensuring minimal radiation exposure to patients. The adoption of gallium-68-based imaging agents such as PSMA-targeted tracers has revolutionized cancer diagnostics, improving detection accuracy and clinical outcomes.
The market is segmented based on application into oncology, neurology, cardiology, and others. Among these, the oncology segment dominates due to the high prevalence of cancer globally and the increasing need for early detection tools. By end user, hospitals and diagnostic imaging centers account for the largest market share, driven by the rising number of PET scan procedures.
Key Market Drivers
One of the primary drivers of the gallium-68 market is the rising incidence of prostate cancer and neuroendocrine tumors. These conditions require highly sensitive diagnostic techniques, where gallium-68-based PET imaging offers superior accuracy compared to conventional imaging methods. Additionally, the growing adoption of nuclear medicine and radiopharmaceuticals is significantly boosting market demand.
Technological advancements in generator-based production methods are also enhancing accessibility and efficiency. The germanium-68/gallium-68 generator system enables on-site production, reducing dependency on large-scale cyclotron facilities and improving supply chain dynamics.
Market Challenges
Despite its promising growth, the gallium-68 market faces certain challenges. The short half-life of the isotope limits its storage and transportation, requiring efficient logistics and timely usage. This can increase operational complexity for healthcare providers. Additionally, regulatory hurdles and the high cost of radiopharmaceutical production may restrain market expansion to some extent.
Regional Insights
Geographically, North America holds a significant share of the gallium-68 market due to advanced healthcare infrastructure and early adoption of innovative diagnostic technologies. Europe follows closely, driven by strong research activities and government support for nuclear medicine. Meanwhile, the Asia-Pacific region is expected to witness the fastest growth during the forecast period, owing to increasing healthcare investments, rising awareness, and expanding diagnostic capabilities.
Top Players in the Gallium-68 Market
- Novartis AG
- Telix Pharmaceuticals (US) Inc
- IRE-ELiT SA
- ITM Medical Isotopes GmbH
- Eckert & Ziegler Radiopharma GmbH
- ARTMS Inc
- IBA Radiopharma Solutions
- Cardinal Health
- Rosatom
- Evergreen Theragnostics Inc
These companies are focusing on strategic collaborations, product innovation, and geographic expansion to strengthen their market presence and meet growing global demand.
Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPRE00029992
Future Outlook
The future of the gallium-68 market looks promising, with increasing research and development activities paving the way for new applications in diagnostics and theranostics. The integration of gallium-68 with targeted therapies is expected to unlock new opportunities in personalized medicine. Furthermore, advancements in production technologies and the development of novel radiotracers will enhance the efficiency and scalability of gallium-68 applications.
As healthcare systems continue to prioritize early diagnosis and precision medicine, the demand for gallium-68 is anticipated to rise steadily. Emerging economies are also expected to play a crucial role in market expansion, driven by improving healthcare infrastructure and growing investments in nuclear medicine.
Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish
Related Reports
Immunoassay Reagents and Devices Market Size, Trends & Growth by 2034
RNA Extraction Kits Market Share, Demand & Growth by 2034
Contact Us
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
Email: sales@theinsightpartners.com
About Us
The Insight Partners is a leading provider of actionable market intelligence and consulting services across various industries. Our research reports combine advanced analytics, expert insights, and reliable data to help organizations identify new opportunities, optimize strategies, and achieve sustainable growth. We specialize in delivering in-depth market studies covering healthcare, technology, manufacturing, and emerging sectors.